Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease
- PMID: 25856768
- PMCID: PMC4450972
- DOI: 10.1097/MIB.0000000000000391
Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease
Abstract
Background: Comorbidity and polypharmacy, more prevalent among older persons, may impact the treatment of patients with inflammatory bowel disease (IBD). The aims of this study were to assess the frequency of polypharmacy and medication interactions within a cohort of older patients with IBD and describe IBD treatment patterns.
Methods: Cohort study of 190 patients with IBD 65 years or older followed at a tertiary IBD referral center from 2006 to 2012. Data collected included demographics, IBD-specific characteristics including disease activity, and comorbidity. Medication histories were extracted from medical records, and data were used to classify polypharmacy, frequency, and severity of potential medication interactions and inappropriate medication use.
Results: Older patients with IBD were prescribed an average of 9 routine medications. Severe polypharmacy (≥10 routine medications) was present in 43.2% of studied patients and associated with increasing age, greater comorbidity, and steroid use. Overall, 73.7% of patients had at least 1 potential medication interaction, including 40% of patients with potential IBD medication-associated interactions. Chronic steroids were prescribed to 40% of the older patients including 24% who were in remission or with mild disease activity. Only 39.5% of patients were on immunomodulators and 21.1% on biologics. Approximately, 35% of patients were given at least 1 Beers inappropriate medication and almost 10% were receiving chronic narcotics.
Conclusions: Older patients with IBD are at increased risk for severe polypharmacy and potential major medication interactions especially with increasing comorbidity and chronic steroid use. Steroid-maintenance therapies are prevalent among the older patients with IBD with lower utilization of steroid-sparing regimens.
Conflict of interest statement
C. Y. Ha: AbbVie Scientific Advisory Board. A. Parian has no conflicts of interest to disclose.
Figures
Similar articles
-
Age Disparities in the Use of Steroid-sparing Therapy for Inflammatory Bowel Disease.Inflamm Bowel Dis. 2016 Aug;22(8):1923-8. doi: 10.1097/MIB.0000000000000817. Inflamm Bowel Dis. 2016. PMID: 27416039 Free PMC article.
-
Prevalence and Appropriateness of Polypharmacy in Older Adults with Inflammatory Bowel Diseases.Dig Dis Sci. 2024 Mar;69(3):766-774. doi: 10.1007/s10620-023-08250-3. Epub 2024 Jan 25. Dig Dis Sci. 2024. PMID: 38273076
-
Severe Polypharmacy Increases Risk of Hospitalization Among Older Adults With Inflammatory Bowel Disease.Am J Gastroenterol. 2025 Apr 1;120(4):844-855. doi: 10.14309/ajg.0000000000003036. Epub 2024 Aug 20. Am J Gastroenterol. 2025. PMID: 39162710
-
Therapeutic challenges of managing inflammatory bowel disease in the elderly patient.Expert Rev Gastroenterol Hepatol. 2016 Sep;10(9):1005-10. doi: 10.1080/17474124.2016.1179579. Epub 2016 Apr 28. Expert Rev Gastroenterol Hepatol. 2016. PMID: 27087144 Review.
-
Medical management of inflammatory bowel disease in the elderly: balancing safety and efficacy.Clin Geriatr Med. 2014 Feb;30(1):67-78. doi: 10.1016/j.cger.2013.10.007. Clin Geriatr Med. 2014. PMID: 24267603 Review.
Cited by
-
The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors.J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S68-S72. doi: 10.1093/jcag/gwy051. Epub 2018 Nov 2. J Can Assoc Gastroenterol. 2019. PMID: 31294386 Free PMC article.
-
Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease.Inflamm Bowel Dis. 2016 Jun;22(6):1435-41. doi: 10.1097/MIB.0000000000000747. Inflamm Bowel Dis. 2016. PMID: 26978725 Free PMC article.
-
Time Trends in Glucocorticoid Use in Rheumatoid Arthritis During the Biologics Era: 1999-2018.Semin Arthritis Rheum. 2023 Aug;61:152219. doi: 10.1016/j.semarthrit.2023.152219. Epub 2023 May 5. Semin Arthritis Rheum. 2023. PMID: 37172495 Free PMC article.
-
Steroid use and misuse: a key performance indicator in the management of IBD.Frontline Gastroenterol. 2020 Apr 2;12(3):207-213. doi: 10.1136/flgastro-2019-101288. eCollection 2021. Frontline Gastroenterol. 2020. PMID: 33907617 Free PMC article. Review.
-
How to manage IBD in the 'elderly'.Frontline Gastroenterol. 2019 Nov 15;11(6):468-477. doi: 10.1136/flgastro-2019-101218. eCollection 2020 Oct. Frontline Gastroenterol. 2019. PMID: 33101625 Free PMC article. Review.
References
-
- 2010 Census Data on Aging. Available at: http://www.aoa.gov/aoaroot/aging_statistics/Census_Population/census2010.... Accessed December 5, 2011.
-
- Catlin A, Cowan C, Hartman M, et al. National health spending in 2006: a year of change for prescription drugs. Health Aff (Millwood). 2008;27:14–29. - PubMed
-
- Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107–1116. - PubMed
-
- Field TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med. 2001;161:1629–1634. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical